With strong CYP3A4/P-gp inhibitors
Strong CYP3A4 or P-gp inhibition can markedly increase sirolimus exposure and toxicity.
Interaction evidence sourcePrescription immunosuppressant / longevity
Prepared by the ezGLP team. Sources last checked .
Also known as Rapamycin
Routes represented in the knowledgebase: Oral.
FDA-approved immunosuppressant; anti-aging use is off-label and has not established lifespan or healthspan benefit in humans. Infection and malignancy risks are substantial.
No validated PubMed or DOI link is currently curated for this entry.
Common or reported: edema, high triglycerides or cholesterol, hypertension, diarrhea, nausea, stomatitis, anemia.
Serious or important: serious infection, impaired wound healing, renal dysfunction, interstitial lung disease, thrombotic microangiopathy, embryo-fetal toxicity.
Safety evidence sourceThese are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.
Strong CYP3A4 or P-gp inhibition can markedly increase sirolimus exposure and toxicity.
Interaction evidence sourceStrong CYP3A4 or P-gp induction can reduce sirolimus exposure and cause treatment failure.
Interaction evidence sourceGrapefruit inhibits intestinal CYP3A4 and can increase sirolimus exposure.
Interaction evidence sourceImmunosuppression can permit vaccine-related infection and reduce vaccine response.
Interaction evidence sourceSummarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.
For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.